Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial
出版年份 2020 全文链接
标题
Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial
作者
关键词
-
出版物
EUROPEAN RADIOLOGY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-09-30
DOI
10.1007/s00330-020-07249-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
- (2020) Flora Mulkey et al. Journal for ImmunoTherapy of Cancer
- irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
- (2019) Jean-Christophe Pignon et al. CLINICAL CANCER RESEARCH
- Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth
- (2019) Kaitlyn Johnson et al. EUROPEAN JOURNAL OF CANCER
- Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non–Small Cell Lung Cancer
- (2019) Lucian Beer et al. CLINICAL NUCLEAR MEDICINE
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
- (2018) M. Tazdait et al. EUROPEAN JOURNAL OF CANCER
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
- (2018) Caroline Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
- (2018) Julia A Beaver et al. LANCET ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- iRECIST: A clarification of tumour response assessment in the immunotherapy era
- (2017) Charles Ferté et al. EUROPEAN JOURNAL OF CANCER
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Pseudoprogression and Immune-Related Response in Solid Tumors
- (2015) Victoria L. Chiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Variability in Assessing Treatment Response: Metastatic Colorectal Cancer as a Paradigm
- (2014) B. Zhao et al. CLINICAL CANCER RESEARCH
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now